Skip to main content
Canna~Fangled Abstracts

Tolerability of long-term cannabidiol supplementation to healthy adult dogs

By November 27, 2023December 1st, 2023No Comments

doi: 10.1111/jvim.16949.

Online ahead of print.
Affiliations 

Free article

Abstract

Background: Cannabidiol (CBD) has therapeutic potential in companion animals. Shorter-term studies have determined that CBD is well tolerated in dogs with mild adverse effects and an increase in alkaline phosphatase (ALP) activity. There is need to assess CBD’s long-term tolerability.

Hypothesis: Determine the long-term tolerability of CBD administered PO to healthy dogs for 36 weeks at dosages of 5 and 10 mg/kg body weight (BW)/day. Our hypothesis was that CBD would be well tolerated by dogs.

Methods: Eighteen healthy adult beagle dogs were randomly assigned to 3 groups of 6 each that received 0, 5, or 10 mg/kg BW/day CBD PO. Dogs were adapted to their housing for 3 weeks and received treatment for 36 weeks once daily with food. Adverse events (AEs) were recorded daily. Blood biochemistry profiles were monitored every 4 weeks. Data were analyzed as repeated measures over time using a mixed model, with significance at α = 0.05.

Results: The 0 and 5 mg/kg treatment groups had similar fecal scores, and the 10 mg/kg treatment group had higher frequency of soft feces. No other significant AEs were noted. An increase (P < .0001) in ALP activity occurred in groups that received CBD. Remaining blood variables were within reference range.

Conclusions and clinical importance: Chronic administration of CBD in healthy dogs at 5 mg/kg was better tolerated than 10 mg/kg, and both dosages caused an increase in ALP activity. Although our data does not indicate hepatic damage, it is recommended to monitor liver function in dogs receiving CBD chronically.

Keywords: canine, cannabidiol, health, hemp, safety

PubMed Disclaimer

References

REFERENCES

    1. Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33:1357-1392. doi:10.1039/c6np00074f
    1. Corsato Alvarenga I, MacQuiddy B, Duerr F, Elam H, McGrath S. Assessment of CBD use in pets according to a national survey in the United States. J Small Anim Pract. 2022;64:513-521.
    1. van Haaften KA, Grigg EK, Kolus C, et al. The emerging role of cannabidiol (CBD) products; a survey exploring the public’s use and perceptions of CBD. Vet Comp Oncol. 2019;14(7):1-11. doi:10.3389/fvets.2018.00338
    1. Corsato Alvarenga I, Panickar KS, Hess H, Mcgrath S. Scientific validation of cannabidiol for management of dog and cat diseases. Annu Rev Anim Biosci. 2023;11:227-246.
    1. White CM. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol. 2019;59(7):923-934. doi:10.1002/jcph.1387

Grants and funding

LinkOut – more resources

  • Full Text Sources


Leave a Reply